All Articles

Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.

Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors.

In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis.

Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy.

On behalf of all of us at the Academy of Oncology Nurse & Patient Navigators (AONN+) and the Journal of Oncology Navigation & Survivorship (JONS), I’d like to personally invite you to submit an abstract for the 13th Annual Navigation & Survivorship Conference to be held in New Orleans, LA, November 2-6, 2022. This is an opportunity to share your evidence-based navigation research studies, quality improvement projects, and best practices utilizing pre- and postdata elements to enhance your program with your navigation and survivorship care colleagues.

Do comorbid diagnoses affect breast cancer screening rates? The authors of this study present their findings.

As a little girl, Tamika Felder dreamed of being on TV. She loved watching the news even at a very young age, had an unwavering curiosity about what was going on in the world, and set her sights on a career in television, which she later achieved. What she didn’t set her sights on was a cervical cancer diagnosis at the age of 25, a radical hysterectomy, and the devastating complete loss of her fertility.

The National Navigation Acuity Team – a collaborative initiative between AONN+ and Astellas – is developing an acuity tool to optimize patient care.

How are you explaining the nuances – and managing expectations – of genetic testing and precision medicine?

Data from electronic health records can successfully be used as infrastructure to mitigate cancer treatment disparities. Here’s how.